Why the study?
The autonomic nervous system may be affected in breast cancer patients, but the prevalence of impaired heart rate variability, its predictors, and clinical impacts remained to be investigated.
Does impaired heart rate variability predict de novo atrial fibrillation or all-cause mortality in female breast cancer patients?
Population
136 female breast cancer patients undergoing 24 h Holter ECG monitoring
Comparison
Patients with impaired HRV vs normal HRV
Design
Retrospective cohort study
Authors
Loading...
Impaired HRV may occur in breast cancer patients; leaves open its value for cardiotoxicity prediction or monitoring.
Does impaired heart rate variability predict de novo atrial fibrillation or all-cause mortality in female breast cancer patients?
In female breast cancer patients, impaired heart rate variability is associated with hypertension and an increased risk of de novo atrial fibrillation, but it does not predict all-cause mortality.
Ceren et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: